IGMS — IGM Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $76.57m
- -$27.73m
- $2.68m
- 29
- 81
- 25
- 42
Annual cashflow statement for IGM Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -81.4 | -165 | -221 | -246 | -196 |
| Depreciation | |||||
| Non-Cash Items | 10.4 | 29.3 | 54 | 52.6 | 40.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.04 | 6.45 | 155 | -6.69 | -7.11 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -67.9 | -125 | -5.85 | -192 | -153 |
| Capital Expenditures | -17.5 | -13.2 | -10.2 | -12.4 | -5.85 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 75.8 | 28.7 | -215 | 80.7 | 70 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 58.3 | 15.5 | -226 | 68.4 | 64.2 |
| Financing Cash Flow Items | -1.05 | -0.65 | 0.895 | 1.38 | 0.841 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 215 | 2.48 | 219 | 115 | 2.39 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 205 | -107 | -12.1 | -8.81 | -86.5 |